公开(公告)号：US11865359B2

公开(公告)日：2024-01-09

申请号：US16728803

申请日：2019-12-27

Applicant: IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

Inventor： Harold Walder ,  Frederic A. Bourke, Jr. ,  Zakaryae Fathi ,  Wayne F. Beyer, Jr. ,  Mark Dewhirst ,  Mark Oldham ,  Justus Adamson ,  Michael Nolan

IPC: A61N5/06 ,  A61K41/17 ,  A61K39/00 ,  A61K41/00 ,  A61K49/04 ,  A61N5/02 ,  A61N5/10

CPC classification number: A61N5/062 ,  A61K39/0011 ,  A61K41/0066 ,  A61K41/17 ,  A61K49/0423 ,  A61N5/022 ,  A61N5/10 ,  A61N5/1081 ,  A61K2039/585 ,  A61N2005/0627 ,  A61N2005/0659 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/1089 ,  A61N2005/1098

Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.

公开(公告)号：US11577092B2

公开(公告)日：2023-02-14

申请号：US16322178

申请日：2017-08-01

Applicant: IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

Inventor： Harold Walder ,  Frederic A. Bourke, Jr. ,  Zakaryae Fathi ,  Wayne Beyer ,  Mark Oldham ,  Justus Adamson ,  Paul Yoon

IPC: A61K9/00 ,  A61N5/06 ,  A61N5/10 ,  A61K41/00 ,  A61K33/42 ,  A61P35/00

Abstract: A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose distribution. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose comprising a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor.

公开(公告)号：US11571587B2

公开(公告)日：2023-02-07

申请号：US16860623

申请日：2020-04-28

Applicant: IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

Inventor： Frederic A. Bourke, Jr. ,  Harold Walder ,  Zakaryae Fathi ,  Michael J. Therien ,  Mark W. Dewhirst ,  Ian N. Stanton ,  Jennifer Ann Ayres ,  Diane Renee Fels ,  Joseph A. Herbert

IPC: A61N5/06 ,  A61K41/00 ,  A61N5/10

Abstract: A method for treating a disease, disorder, or condition in a subject in need thereof, by administering either or both of (i) at least one photoactivatable pharmaceutical agent, or (ii) a first plurality of energy-emitting particles, into the subject in a region of the disease, disorder, or condition, whereby the administering is performed through inhalation; and applying an applied electromagnetic energy to the subject, wherein the applied electromagnetic energy directly or indirectly activates the at least one photoactivatable pharmaceutical agent, when present, and wherein when the first plurality of energy-emitting particles is present, the first plurality of energy-emitting particles absorbs the applied energy and emits an emitted electromagnetic energy, wherein the emitted electromagnetic energy interacts directly with the region of the disease, disorder, or condition or activates the at least one photoactivatable pharmaceutical agent.

公开(公告)号：US11534622B2

公开(公告)日：2022-12-27

申请号：US15504917

申请日：2015-08-17

Applicant: IMMUNOLIGHT, LLC

Inventor： Frederic A. Bourke, Jr. ,  Zakaryae Fathi ,  Harold Walder

IPC: A61N5/06 ,  A61B18/00 ,  A61B18/18 ,  B82Y30/00 ,  A61N1/40 ,  A61N5/02 ,  A61N5/10 ,  A61N5/067

Abstract: Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by application of an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

公开(公告)号：US11305131B2

公开(公告)日：2022-04-19

申请号：US16554831

申请日：2019-08-29

Applicant: IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

Inventor： Mark Oldham ,  Zakaryae Fathi ,  Wayne F. Beyer ,  Frederic A. Bourke, Jr. ,  Harold Walder ,  Mark DeWhirst ,  Neil L. Spector ,  Paul Yoon ,  Justus Adamson ,  David Alcorta ,  Kim Lyerly ,  Leihua Liu ,  Takuya Osada

IPC: A61N5/06 ,  A61K41/00 ,  A61N5/10 ,  A61K31/352

Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.

公开(公告)号：US11270973B2

公开(公告)日：2022-03-08

申请号：US16995067

申请日：2020-08-17

Applicant: Immunolight, LLC

Inventor： Zakaryae Fathi ,  James Clayton ,  Harold Walder ,  Frederic A. Bourke, Jr.

IPC: C09J9/02 ,  H01L23/00 ,  C08K3/00 ,  B41J2/175 ,  C09J4/00 ,  A61B17/00 ,  A61L24/06 ,  B32B37/12 ,  B32B37/18 ,  B32B38/00 ,  C09J133/08 ,  C09K11/02 ,  C09K11/77 ,  H01L25/065 ,  H01L25/00 ,  B32B3/26 ,  B32B7/14 ,  B32B9/04 ,  C09J11/04 ,  C09J11/06 ,  H01L23/522

Abstract: A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.

公开(公告)号：US11135294B2

公开(公告)日：2021-10-05

申请号：US15770926

申请日：2016-10-26

Applicant: IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

Inventor： Mark Oldham ,  Justus Adamson ,  Mark W. Dewhirst ,  Paul Yoon ,  Harold Walder ,  Frederic A. Bourke, Jr. ,  Zakaryae Fathi ,  Wayne F. Beyer, Jr.

IPC: A61K41/00 ,  A61K31/409 ,  A61N5/06 ,  A61K31/655 ,  A61K33/02 ,  A61K31/525 ,  A61K31/352 ,  A61K31/403 ,  A61K33/24 ,  A61N5/10 ,  A61K31/426 ,  A61K31/47 ,  B82Y5/00

Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.

公开(公告)号：US11077316B2

公开(公告)日：2021-08-03

申请号：US16096174

申请日：2017-04-25

Applicant: Immunolight, LLC

Inventor： Frederic A. Bourke, Jr. ,  Harold Walder ,  Zakaryae Fathi ,  Wayne F. Beyer, Jr.

IPC: A61K31/015 ,  A61N5/06 ,  A61K31/37 ,  A61K31/519 ,  A61K41/00 ,  A61M31/00 ,  A61N1/40 ,  A61N5/02 ,  A61K38/00 ,  A61N1/372 ,  A61N5/04

Abstract: A system and method for emitting a wavelength of energy internal to a medium or internal to a human or animal subject, and methods for using the system in the treatment of a condition, disorder, or disease. The system includes 1) a source configured to produce an initiation signal penetrating at least a part of the medium or the human or animal subject and 2) an insertion device having an electronics assembly unit. The assembly unit includes 1) an emitter configured to emit the wavelength of energy of a predetermined type to treat a disease or disorder in the human or animal subject or to produce a change in the medium and 2) a receiver that receives the signal.

公开(公告)号：US10734353B2

公开(公告)日：2020-08-04

申请号：US16515754

申请日：2019-07-18

Applicant: Immunolight, LLC

Inventor： Zakaryae Fathi ,  Frederic A. Bourke, Jr. ,  Harold Walder

IPC: H01L23/00 ,  B32B5/02 ,  B32B5/18 ,  B32B5/26 ,  B32B7/06 ,  B32B7/12 ,  B32B9/02 ,  B32B9/04 ,  B32B17/00 ,  B32B18/00 ,  B32B21/04 ,  B32B25/04 ,  B32B27/08 ,  B32B27/16 ,  B32B27/30 ,  B32B27/32 ,  B32B27/34 ,  B32B27/36 ,  B32B37/12 ,  B32B38/00 ,  C09J11/06 ,  C09J133/00 ,  C09J133/06

Abstract: A method of and system for adhesive bonding by a) providing a polymerizable adhesive composition on a surface of an element to be bonded to form an assembly; b) irradiating the assembly with radiation at a first wavelength capable of vulcanization of bonds in the polymerizable adhesive composition by activation of sulfur-containing compound with at least one selected from x-ray, e-beam, visible, or infrared light to thereby generate ultraviolet light in the polymerizable adhesive composition; and c) adhesively joining two or more components together by way of the polymerizable adhesive composition.

公开(公告)号：US10709900B2

公开(公告)日：2020-07-14

申请号：US16251973

申请日：2019-01-18

Applicant: IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

Inventor： Frederic A. Bourke, Jr. ,  Harold Walder ,  Zakaryae Fathi ,  Michael J. Therien ,  Mark W. Dewhirst ,  Ian N. Stanton ,  Jennifer Ann Ayres ,  Diane Renee Fels ,  Joseph A. Herbert

IPC: A61K41/00 ,  A61N5/06 ,  A61N5/10

Abstract: A system and method for light stimulation within a medium. The system has a reduced-voltage x-ray source configured to generate x-rays from a peak applied cathode voltage at or below 105 kVp, and a plurality of energy-emitting particles in the medium which, upon radiation from the x-ray source, radiate at a first lower energy than the x-ray source to interact with least one photoactivatable agent in the medium. The method introduces the plurality of energy-emitting particles into the medium, radiates the energy-emitting particles in the medium with x-rays generated from a peak applied cathode voltage at or below 105 kVp; and emits a lower energy than the x-ray source to interact with the medium or with at least one photoactivatable agent in the medium.